Ribomic Inc.
Notice of Execution of Technical Evaluation Agreement for DDS Aptamer Technology
Concluded a technical evaluation agreement for DDS aptamer technology. Consideration of 53,000 million USD will be received and is expected to be recorded as business revenue in the fiscal year ending March 2027. A revision to earnings guidance has already been announced.
Key Figures
- 53,000 million USD: Consideration
- Fiscal year ending March 2027: Expected to be recorded as business revenue
- 157.95 yen: Indicative rate (as of October 19)
AI要約
Summary of the News
Ribomic Inc. announced that it has entered into a technical evaluation agreement with an overseas biotechnology company regarding its DDS aptamer technology. Consideration of 53,000 million USD is expected to be received. The agreement is for the purpose of technical evaluation and does not promise a business alliance or joint research. This is positioned as the sixth initiative in the drug discovery support business.
Future Outlook and Impact
The consideration under this agreement is expected to be recorded as business revenue in the fiscal year ending March 2027. The counterparty will not be disclosed due to a confidentiality agreement, and the impact of exchange rate fluctuations may vary at the time of recognition. This initiative is regarded as important for promoting future R&D and creating new business opportunities.
Ribomic Inc.
Company overview · Stock price · Financial data · All IR
